Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC by Pedro Rocha, MD, Didac Ramal, MD, Enric Ripoll, MD, Laura Moliner, MD, Alex Corbera, MD, Max Hardy-Werbin, MD, PhD, Mayra Orrillo, MD, Álvaro Taus, MD, Flavio Zuccarino, MD, Joan Gibert, Júlia Perera-Bel, David Casadevall, MD, PhD, Edurne Arriola, MD, PhD

Get full text

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study by Laura Moliner, MD, Núria Zellweger, MSc, Sabine Schmid, MD, Martina Bertschinger, MD, Christine Waibel, MD, Ferdinando Cerciello, MD, PhD, Patrizia Froesch, MD, Michael Mark, MD, Adrienne Bettini, MD, Pirmin Häuptle, MD, Veronika Blum, MD, Lisa Holer, MSc, Stefanie Hayoz, PhD, Martin Früh, MD, Samreen Ahmed, FRCP, MD, MBBS, MSc, Shradha Bhagani, MD, Nicola Steele, MD, Hannah-Leigh Gray, BSc, Stephen D. Robinson, MD, Michael Davidson, MD (Res), Samantha Cox, MD, MSc, MBBCh, Taha Khalid, MD, Tom R. Geldart, MD, Luke Nolan, FRCS, PhD, Deborah C. Scott, MBChB (MRCP), Lindsay Hennah, MD, Tom Newsom-Davis, MD, PhD, Emma Rathbone, MD, PhD, Catherine Handforth, MD, Arshi Denton, MD, Shairoz Merchant, PhD, Fiona Blackhall, MD, PhD, Laetitia A. Mauti, MD, Raffaele Califano, MD, Sacha I. Rothschild, MD, PhD

Get full text